| __timestamp | AstraZeneca PLC | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 101881000 |
| Thursday, January 1, 2015 | 4646000000 | 4011000 |
| Friday, January 1, 2016 | 4126000000 | 102026000 |
| Sunday, January 1, 2017 | 4318000000 | 96171000 |
| Monday, January 1, 2018 | 4936000000 | 66449000 |
| Tuesday, January 1, 2019 | 4921000000 | 42672000 |
| Wednesday, January 1, 2020 | 5299000000 | 42534000 |
| Friday, January 1, 2021 | 12437000000 | 3068000 |
| Saturday, January 1, 2022 | 12391000000 | 1400000 |
| Sunday, January 1, 2023 | 8040000000 | 3008000 |
| Monday, January 1, 2024 | 10207000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. AstraZeneca PLC, a global leader, has seen its cost of revenue fluctuate significantly over the past decade. From 2014 to 2023, AstraZeneca's cost of revenue increased by approximately 38%, peaking in 2021 with a staggering 124% rise compared to 2016. This reflects strategic investments and scaling operations. In contrast, Celldex Therapeutics, Inc., a smaller biotech firm, experienced a more volatile trend. Despite a 90% drop in 2022 compared to 2014, Celldex's cost of revenue remained relatively low, highlighting its lean operational model. The stark contrast between these two companies underscores the diverse strategies within the pharmaceutical sector. As AstraZeneca continues to expand its global footprint, Celldex's focus on niche markets offers a compelling narrative of resilience and adaptability.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc
Cost Insights: Breaking Down AstraZeneca PLC and Xenon Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Travere Therapeutics, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Xencor, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: GSK plc vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Celldex Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Celldex Therapeutics, Inc.